key: cord-0700958-190j52zt authors: Maghool, Fatemeh; Valiani, Ali; Safari, Tahereh; Emami, Mohammad Hassan; Mohammadzadeh, Samane title: Gastrointestinal and renal complications in SARS‐CoV‐2‐infected patients: Role of immune system date: 2020-12-07 journal: Scand J Immunol DOI: 10.1111/sji.12999 sha: 8060e928d59acf684aba0ca27cb33d7f38eed813 doc_id: 700958 cord_uid: 190j52zt The recent severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) disease has been accompanied by various gastrointestinal (GI) and renal manifestations in significant portion of infected patients. Beside studies on the respiratory complications of coronavirus infection, understanding the essential immunological processes underlying the different clinical manifestations of virus infection is crucial for the identification and development of effective therapies. In addition to the respiratory tract, the digestive and urinary systems are the major sources of virus transmission. Thus, knowledge about the invasion mechanisms of SARS‐CoV‐2 in these systems and the immune system responses is important for implementing the infection prevention strategies. This article presents an overview of the gut and renal complications in SARS‐CoV‐2 infection. We focus on how SARS‐CoV‐2 interacts with the immune system and the consequent contribution of immune system, gut, and renal dysfunctions in the development of disease. haematuria and acute kidney injury (AKI). [4] [5] [6] [7] The reported incidence of gut complications and acute kidney injury (AKI) in COVID-19 patients ranged from 12% to 61% and 0.5% to 29%, respectively. 8, 9 Patients with atypical gastrointestinal (GI) symptoms have had long-term SARS-CoV-2 infection and needed more antimicrobial treatment than patients without that. Moreover, infected patients who need ICU care are more expected to develop AKI than non-ICU patients. 10 Besides, Stool and urine of SARS-CoV-2-infected patients has been proved to be the potential routes of viral transmission. 11, 12 Multi-organ disorders in SARS-CoV-2 infection infer the presence of virus receptor in these organs. 13, 14 Indeed, small GI epithelial cells and colonocytes express main host cell receptor of SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2), abundantly on their apical surfaces. 15 In addition, ACE2 expression is mostly localized in proximal tubular brush border, and to a less extend in the glomerular visceral and parietal epithelial cells, endothelial, and smooth muscle cells of renal vessels. 16 It seems likely that gut and renal manifestations of SARS-CoV-2 infection as well as the severity of inflammatory response of immune system are largely related to the expression of virus receptor in these organs. This review summarizes the gastrointestinal and renal complications in SARS-CoV-2-infected patients and role of immune system in the pathogenesis of the virus. SARS-CoV-2 is an enveloped virus contains a positivestranded RNA genome which encodes several structural and non-structural proteins. The structural protein S of SARS-CoV-2 is used for virus attachment to ACE2 and virus entrance into the host cells. E, M and N proteins are accessory parts of virus for replication, assembly and host immune response suppression. 17, 18 Upon entrance of SARS-CoV-2, viral genomic RNA or dsRNA is recognized by endosomal and cytoplasmic receptors including toll-like receptor 3 (TLR3), TLR7 and retinoic acid-inducible gene I ( RIG-I) and melanoma differentiation-associated gene 5 (MDA5) and then pro-inflammatory cytokines such as interferon-γ (IFN-γ), inducible protein 10 kD (IP-10), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein 1 alpha (MIP-1A) and tumour necrosis factor-α (TNFα) are expressed. 19, 20 Thereinafter, neutrophils as the first inflammatory immune cells are recruited into the infected sites and their antiviral activities cause cytokine storm and more attraction of immune cells such as monocytes and T cells into the infected area ( Figure 1 ). 21, 22 Afterwards, antigen-presenting cells (APCs) such as dendritic cells (DC) and macrophages phagocyte SARS-CoV-2 and become functionally mature. Both cells increase production of MHC class II costimulatory molecules, cytokines and chemokines, like interleukin-6 (IL-6), IL-12, TNF-α, MIP-1α, RANTES, IP-10 and MCP-1; thereafter, cellular and humoral immune responses such as killing the infected cells by cytotoxic T cells and producing the anti-SARS-CoV-2 antibodies by plasma cells are occurred as a result of matured APCs activities. [23] [24] [25] On the other hand, it has reported that secreted IFNs by neutrophils and APCs could prevent virus progression, stimulate phagocytosis of antigens by DCs and macrophages, and target infected cells by natural killer (NK) and T cells. 26, 27 However, SARS-CoV-2 may cause severe viral infection through prolonging virus survival in the host by suppressing IFN production via different mechanisms, including ubiquitination and degradation of RNA sensor adaptor molecules, mitochondrial antiviral signalling protein (MAVS) and tumour necrosis factor receptor-associated factor 3/6 (TRAF3/6), prevention of interferon regulatory factor 3 (IRF3) nuclear translocation, and repression of histone modification. [28] [29] [30] In severe infected patients, NK cells, CD4+ and CD8+ T cells are reduced, although the CD4+/CD8+ T cells ratio are un-affected; therefore, it has suggested that lymphopenia is a hallmark finding in SARS-CoV-2 infection. [31] [32] [33] Several studies have documented the significant role of T cells in the pathogenesis of SARS-CoV-2 infection. T cells, especially | 3 of 17 virus-specific CD4+ T and CD8+ T cells, have important roles in removing virus-infected cells and balancing immune responses to pathogens. [33] [34] [35] T cells could rescue organs from severe damage by the control of excessive innate immune responses. Indeed, T helper cells promote production of antiviral antibodies by activating CD4+ T-dependent B cells and induction of pro-inflammatory cytokines through the NF-kβ signalling pathway. 31, 36 Elevation of Th1 and Th17 cells along with high expression of IFNγ and IL17 were observed in SARS-CoV-2 patients. IL17 stimulates recruiting of neutrophils and monocytes into the inflamed infected regions and induces cytokine cascade. Poor outcome in viral infected patients can be attributed to increased IL-17 and reduced IFN-γ and IFNI production. [37] [38] [39] Regulatory T cells (Tregs), which identifies them as immunosuppressive cells, are moderately amplified in mild SARS-CoV-2 infection. Elevation of Treg cells is associated with the pathogenesis of COVID-19 disease. 40, 41 It has reported that in severe SARS-CoV-2 infection, the naive/memory T cell ratio is higher than that in mild infection. Memory viral-specific T cells, as infection-fighting T cells, would be exist in the improved patients after clearance of SARS-CoV-2 infection and, upon re-exposure to the virus, are rapidly converted into effector T cells and provided necessary response to overcome the virus infection. These memory T cells are restricted to epitopes of structural viral proteins including the S, M, and N proteins and can induce effective responses against SARS-CoV-2. [42] [43] [44] Reduction of T cells in COVID-19 patients is might be because of a BH3-like region in the C-terminal cytosolic domain of SARS-CoV-2 protein, which could facilitate binding of virus protein to Bcl-xL in the T cells and induce T cells apoptosis. 45 Humoral immunity is fundamental element for controlling the SARS-CoV-2 infection through neutralization of viruses and lysis of infected cells via complement activation or antibody-dependent cytotoxic cells (ADCC). 46 In severe SARS-CoV-2 infection, IgA, IgG and IgM levels are similar to that in mild infection. 32, 33 Anti-SARS-CoV-2 antibodies, such as IgG, IgM and IgA, are at the highest level in the serum of infected patients within 20-30 days after onset of illness, and sustained for about 5 months thereafter. However, serum IgG can be detected early (about 4 days) after the onset of disease. 47 IgG and IgA are the most important antibodies in the serum and mucus, respectively. 48 Among them, anti-S protein antibody is a strongly neutralizing anti-SARS-CoV-2 antibody with either high or low avidity binding activity. This antibody can induce protective immunity against many variants of S protein in different SARS-CoV-2 strains. 49, 50 Despite the antiviral cellular and humoral responses, SARS-CoV-2 escapes from immune system responses via The immune system in GI tract, intestinal mucosal immune system or gut-associated lymphoid tissue (GALT), constitutes the largest immune component with three different structures: epithelial and mucosal barrier, the lamina propria, and the Peyer's patches (PPs) (Figure 2 ). 9 The mucosal barrier, as a component of immune system, consists of the small intestinal epithelium and Paneth cells which secrete antimicrobial peptides (AMPs). 55 This barrier participates in the immune surveillance of the gut and sends signals to the mucosal immune system by producing cytokines and chemokines. Immune cells of mucosal barrier contain innate lymphoid cells, intraepithelial lymphocytes, NK cells, cytolytic and immunoregulatory αβ+ and γδ+ T cells, DCs and Tregs. [56] [57] [58] The lamina propria, the lower layer of intestinal epithelial cells, carries a large population of innate lymphoid cells (ILCs), B, NK and T cells (γδ+ T, Th17). T cells in the lamina propria quickly respond to the signals from the lumen and initiate inflammatory and anti-inflammatory responses through secreting cytokines (IL17, IL22, IFN-γ and IL26), and inducing defensins and chemokines. 54, 56, 59 Peyer's patches are an important source of precursor IgA-producing cells in the mucosa of the small intestine. PPs contain proliferating B cells, population of CD4 T cells, dendritic cells, follicular dendritic cells and macrophages. M cells, the specialized cells in PPs, phagocyte bacteria, viruses, proteins, and inert particles and transcytose them into the PPs to trigger the appropriate immune responses. 56,59-61 The first step of SARS-CoV-2 infection is the virus entry to the cell via its target, ACE2 receptor. This receptor is abundantly expressed (100 times than that in the lung) in the epithelial cells of the stomach, duodenum, ileum, and rectum as well as cholangiocytes and hepatocytes of the liver, while less expression of ACE2 receptor has demonstrated in oesophageal mucosa. 15, 62, 63 The highly expression of ACE2 receptor in the absorptive enterocytes of the ileum and colon suggests a potential explanation for some digestive symptoms such as diarrhoea observed in many COVID-19 patients. In the second step, new virions will be assembled through synthesizing viral-specific RNA and proteins of positive-strand viral RNA, and released in to the GI tract. 64, 65 New virions and released SARS-CoV-2 could destruct epithelial cells, induce immune responses and trigger cytokine storm. Some in vivo studies suggested that SARS-CoV-2 may affect absorption of tryptophan through ACE2, resulting in decreased antimicrobial peptide, which in turn leads to an altered gut microbial composition. Indeed, gut microbiota dysbiosis has been reported in some SARS-CoV-2-infected patients, and treatment with probiotic has also been suggested, but it has not been confirmed yet. 66, 67 Cytokine storm in COVID-19 patients is accompanied by a general inflammatory reaction, abnormal immune responses and several organ dysfunctions, such as digestive injury which may lead to more severe disease and even death. 63, 68 Experimental studies suggested that lung infection can be secondary to a primary gut viral infection; nevertheless, whether intestinal injury caused by the virus could be a secondary response to primary general inflammation or as a result of primary intestinal infection, or a combination of both, needs further investigation. 63, 69 Up to 50% of patients with COVID-19 represent liver enzyme abnormalities which are related to hepatic damage. ACE2 appears to play an important role in the pathogenesis of hepatic injury in COVID-19. High expression of ACE2 on the cholangiocytes and hepatocytes of the liver may explain a direct cytotoxic effect of the virus against hepatic cells. It has suggested that SARS-CoV-2 may deteriorate hepatic injury through various pathogenic mechanisms such as direct cytopathic effect on cholangiocytes and hepatocytes, inflammatory cytokine storm, hypoxic injury of the liver and drug toxicity. However, further studies are required to determine the exact pathogenesis of the liver injury seen in COVID-19 patients. [70] [71] [72] Intestinal microbiome dysbiosis is accompanying by bilateral deviation in the connection between the gut and vital organs such as the lungs. In addition, changes in the microbial community of the lungs can affect the gut microbiome composition. It has therefore been suggested that the 'gutlung axis' is like a two-way communication network where several respiratory infections are accompanied by digestive symptoms and, in other way, gut microbiome dysbiosis is linked to respiratory infections. Additionally, in gut-lung axis, immune cells from the gastrointestinal tract migrate through the bloodstream to the lung and influence immune responses within the lung. Further, viral lung infections can change the composition of intestinal bacteria, where gut microbiota regulate adaptive immune responses against the lung pathogens. Similar crosstalk between the gut and lungs has been suggested in SARS-CoV-2 infection. Indeed, following infection of lung cells with SARS-CoV-2, intestinal immune disorder and diarrhoea can occur due to the effect of CD4+ T cells that reached it through the gut-lung axis. 60, 69, 73 Early studies on SARS-CoV-2 infection reported that diarrhoea (2%-10.1%), nausea and vomiting (1%-3.6%) are not usual symptoms in infected patients, Table 1 . 10, 74 However, later studies revealed that gastrointestinal symptoms are frequent and associated with severe form of disease. 75 is one of the atypical gastrointestinal symptoms in COVID-19 patients. 74 Viral diarrhoea in SARS-CoV-2 infection might be occurred due to the induction of inflammation by SARS-CoV-2 in the ACE2+ epithelium. Indeed, inflammation can cause epithelial atrophy and disrupt the balance between the absorption and secretion of water and electrolytes. [76] [77] [78] [79] Diarrhoea can also be induced by a wide variety of antiviral and antibacterial medications that patients may receive. 60 In addition, inhibited innate immune responses by SARS-CoV-2 might permit infiltration, replication and infection of opportunistic intestinal bacteria in the epithelium, resulting in bacterial diarrhoea. 80 However, in mild viral diarrhoea, upregulation of immune inhibitory cytokine TGF-β may induce apoptosis of antiviral T cells, and an anti-apoptotic response of host cells may reduce inflammation and destruction of intestinal epithelial cells (Figure 3 ). 45,81 An important concern in SARS-CoV-2 pandemic is patients with immune-mediated disease like IBD (inflammatory bowel diseases) and concurrent SARS-CoV-2 infection. It seemed that patients with IBD like Crohn's disease and ulcerative colitis are more susceptible to viral infections. 149, 150 IBD as an inflammatory condition in the colon and small intestine is caused by an excessive immune response against luminal bacteria in the GI tract. 151 The common medications in IBD are immunosuppressive drugs, mainly anti-TNF agents. 152 Remarkable points in IBD patients are the high expression of ACE2 in the GI tract accompanied by immune system suppression, which increase the susceptibility of patients to the viral infections ( Figure 4) . 153, 154 However, severe SARS-CoV-2 infection or high mortality rate has not been reported in treating IBD patients; therefore, an international consensus is that IBD patients are not more susceptible to SARS-CoV-2 infection than individuals without IBD. In fact, there are two forms of ACE2 in IBD patients which are distinct in structure and function: (a) membranous ACE2, consists of 2 domains, extracellular domain which is bind to S protein of SARS-CoV-2, and trans-membrane domain which is connector of extracellular domain and cell membrane and (b) soluble ACE2, which contains an extracellular domain of ACE2 without any cell membrane connector. 153, 155, 156 High levels of soluble ACE2 in IBD patients could bind to SARS-CoV-2, prevent virus interactions with membranous ACE2 and consequently decrease the patients' susceptibility to the virus. 156 On the other hand, it was thought that suppression of cytokine storm-driven inflammation by immunosuppressive drugs (azathioprine, methotrexate) might increase infection susceptibility, but interestingly, it has revealed that the effects of anti-inflammatory drugs on the immune system may not only be beneficial for diminishing the mucosal inflammation, but also for avoiding SARS-CoV-2 pneumonia. 152 an increase in pro-inflammatory cytokines such as IL-1, TNF-α or IL-6 is related to the severity of gut inflammation, so cytokines modulation in immune cells may be a major therapeutic management of IBD patients. [158] [159] [160] However, usage of more than one immunosuppressive drug could increase the risk of SARS-CoV-2 infection. 157 Viral infection of gastrointestinal cancer patients such as colorectal cancer (CRC) is another area of concern during SARS-CoV-2 pandemic. ( Figure 5 ). It has reported that about 1%-20% of SARS-CoV-2-infected patients in China and Italy had a history of active cancer and fatality rate in these patients was more than two times higher than in the general. [161] [162] [163] In fact, high expression of immunoinhibitory cytokines and proteins such as TGFβ, IL10, programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) inhibit antitumour responses of immune system and raise the possibility of viral infection. [164] [165] [166] Furthermore, anticancer treatments including chemotherapy or surgery have negative effect on the immune system and cause systemic immunosuppressive status. 161 Consequently, in CRC patients, suppressed immune system could not induce the essential antiviral responses against SARS-CoV-2, and infection of ACE2+ gastrointestinal epithelial cells with SARS-CoV-2 may cause more severe symptoms than in non-cancer patients. 161, 163, 167 The kidneys may be affected in some bacterial/viral infections through their functional activities in clearance of metabolic waste products, toxins, drugs, circulating cytokines and blood borne proteins. 169, 170 Elimination of microbial components and cytokines by renal filtration could limit immune cell activation and inflammation, while long-term exposure of immune cell to cytokines and toxins could lead to persistent stimulation of immune system and cause cytokine storm and consequently tissue damages. 168, 170, 171 In the kidneys, peripheral tolerance is maintained by the renal resident immune cells consisting of DCs, macrophages and lymphocytes, in the absence of immunological danger (bacterial and viral) signals. 172, 173 However, during pathogenic infections, the direct and indirect immune-mediated renal damages can be created respectively via targeting the specific renal antigens and through bystander effects of immune system responses. [166] [167] [168] 171 9 | PATHOPHYSIOLOGY OF In COVID-19 patients, viral RNA is detectable in kidney tissue and urine, and the presence of virus particles in the tubular epithelial cells, podocytes and glomerular capillary endothelium has been demonstrated. It has been shown that the ACE2 expression in the kidneys is higher (about 100-fold) than respiratory organs. In addition, according to histopathological findings, SARS-CoV-2 can exert direct cytopathic effect on the infected renal cells. 8 Therefore, kidney may be an essential target organ for SARS-CoV-2 infection. 74, 174, 175 F I G U R E 5 SARS-CoV-2 and cancer: Radiation therapy and chemotherapy suppress inflammatory cells production which predisposes CRC patients for SARS-CoV-2 infection. DC, dendritic cell; MQ, macrophage; Treg, T regulatory cell 10 | GUT-KIDNEY AXIS, SARS- The kidney and the gut share a bidirectional association of synergy during homoeostasis known as the gut-kidney axis, which can be divided into metabolism-dependent and immune pathways. 176, 177 The first pathway is mainly mediated by the gut microbiome metabolites that can regulate the host physiological functions, while in the second one, the connection between the gut and the kidneys is mainly through the components of the immune system. 176, 178 Crosstalk between these two pathways also plays a critical role in keeping the balance of the gut-kidney axis. Therefore, disruption of this bidirectional communication may lead to severe complications such as AKI and chronic kidney disease (CKD). [178] [179] [180] AKI has been reported to occur in 6% of SARS-CoV-2infected patients. 181, 182 AKI is characterized by rapid deterioration in renal function, which results in the build-up of toxic waste products and disruption of internal homoeostasis. Multiple aetiologies may be contributing to AKI, and medication-induced nephrotoxicity is a relatively common cause among them which mostly affects the tubulointerstitial compartment. 183, 184 The pathophysiological mechanism of drug-induced nephrotoxicity is complex and often mediated by intraglomerular haemodynamic changes, inflammation, and defect in tubular secretion, uric acid deposition, and rhabdomyolysis. 185, 186 SARS-CoV-2-mediated AKI could be due to the cytotropic effect of the virus and systemic inflammatory response induced by cytokines ( Figure 6 ). 55 Incidence of AKI might be affected by multi-factors and be associated with death in severe SARS-CoV-2 infection. 182, 187 Furthermore, cytokine storm may play a main role in the immunopathology of AKI. Indeed, once SARS-CoV-2 infiltrates into the renal cells, innate immune system and inflammation responses might be trigger a cytokine storm, which induces hypoxia, shock, and rhabdomyolysis and thus causes kidney injury. [188] [189] [190] It has been proposed that in COVID-19 patients, cytokine storm is an underlying mechanism of the 'viral sepsis' and multiple-organ failure, such as AKI. 60 Additionally, the dehydration resulted from fever or diminished intake of fluids in these patients, reduces glomerular filtration rate and causes AKI. 15, 191, 192 On the other hand, secreted anti-SARS-CoV-2 antibodies bind to viral antigens and lead to the formation of virus-antibody immune complexes. Deposition of these immune complexes on the renal cells along with antiviral humoral and cellular immune responses (specific antibody or T lymphocyte) might destruct kidney organs. 183, 193, 194 Immunocompromised hosts are another high-risk group of patients such as haemodialysis patients. Blood samples analysis of these patients with SARS-CoV-2 infection has F I G U R E 6 SARS-CoV-2 and acute kidney injury: Immune system responses against SARS-CoV-2 and cytopathic effect of SARS-CoV-2 may cause acute kidney injury | 11 of 17 indicated a notable decrease in helper and cytotoxic T cells, NK cells counts, and low levels of inflammatory cytokines compared to non-haemodialysis patients with SARS-CoV-2 infection. 13, 195 In fact, lymphopenia in dialysis and chronic renal failure patients is a common finding which is related to the disruption of regulatory mechanisms of apoptosis. 196, 197 Decreased immune response and cytokine release in haemodialysis patients increase susceptibility of these patients to the mild SARS-CoV-2 infection without serious pneumonia. The reason of death in these patients is apparently not associated to pneumonia. However, these patients are at higher risk of SARS-CoV-2 infection and further care is essential in the management of haemodialysis patients in SARS-CoV-2 pandemic. 13, 195, 198 13 | MANAGEMENT OF Besides to the direct effects of SARS-CoV-2, infected people might be at risk of GI complications that should be managed. Diarrhoea is one of the most common GI manifestation in one-third to one-half of COVID-19 patients. Liver enzymes may also be elevated, but acute liver failure has not been reported so far in infected patients. Many of the treatments prescribed for COVID-19 patients may have GI and hepatic complications and should be considered in the differential diagnosis. 199 Thus, it is important to monitor the baseline liver enzyme activity both prior to starting and during treatment. Moreover, before starting treatment, the patient should be checked for the presence of chronic viral hepatitis, hepatitis B virus (HBV) and hepatitis C virus (HCV), and also for the risk factors of chronic liver disease, especially alcohol consumption. Major American gastroenterological societies have recommended postponing non-emergency endoscopies and using personal protective equipment in emergency endoscopies. [199] [200] [201] For IBD patients, it is recommended that immunosuppressive drugs be delayed until the symptoms of COVID-19 have resolved; however, the recommended management for severe GI diseases is mainly focused on prevention and supportive measures (64, 202 ). In COVID-19 patients with renal involvement, guidelines for supportive care in renal disease (eg regular control of urinary output and blood creatinine, avoidance of nephrotoxins, and haemodynamic monitoring) should be followed to reduce the severity of AKI in these patients. Use of lung-protective ventilation has recommended in order to minimizing both volutrauma and barotrauma, and reducing the risk of new or worsening AKI. Moreover, fluid balance should be adjusted according to fluid responsiveness and tolerance test. Because COVID-19 patients commonly have a fever and fluid resuscitation is usually not performed prior to admission, volume depletion may be common in patients at the time of admission. Thus, in order to prevent AKI, hypovolaemia should be corrected. 203, 204 15 | CONCLUSION Expression of ACE2 receptors, which are widely expressed in various organs including the respiratory tract, GI tract and kidneys, is making them potential targets for SARS-CoV2 infection. COVID-19 patients may develop a variety of gastrointestinal symptoms (ie nausea, vomiting and diarrhoea) which may due to the immune system responds to viral infection. For instance, induction of cytokine storm and inflammation in the infected ACE2+ epithelium and/or inhibited innate immune responses could induce severe viral diarrhoea, while upregulation of inhibitory cytokines and reduction of antiviral T cells could reduce inflammation and destruction of intestinal epithelial cells which may result in mild diarrhoea. Severe clinical manifestations and poor prognosis might take place in COVID-19 patients with hepatic complications. Thus, the liver function should be monitored before and during treatment to diminish the liver-related complications in these patients. In IBD patients with SARS-CoV2 infection, immunosuppressive drugs can be temporarily withheld until the resolution of active infection. However, in CRC patients, high expression of immunoinhibitory factors and anticancer treatments may suppress the immune system; thereby the immune system could not induce the essential antiviral responses against SARS-CoV-2. On the other hand, cytokine storm, anti-SARS-CoV-2 antibodies, immune complexes and activated immune cells may cause severe renal damages such as AKI in COVID-19 patients. Use of lung-protective ventilation is recommended to prevent worsening of AKI, and more care has been advised for immunocompromised patients such as haemodialysis patients in the COVID-19 pandemic. Consequently, understanding the immune mechanisms underlying GI tract and kidney injury in SARS-CoV-2 infection will likely provide more effective treatment and reducing mortality and morbidity of infected patients. Progress and prospects on vaccine development against SARS-CoV-2 Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV COVID-19 pandemic, coronaviruses, and diabetes mellitus COVID-19: consider cytokine storm syndromes and immunosuppression COVID-19: gastrointestinal manifestations and potential fecal-oral transmission The clinical characteristics of pneumonia patients co-infected with 2019 novel coronavirus and influenza virus in Wuhan Laboratory parameters in detection of COVID-19 patients with positive RT-PCR; a diagnostic accuracy study Is the kidney a target of SARS-CoV-2? Endothelial-podocyte crosstalk: the missing link between endothelial dysfunction and albuminuria in diabetes Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study Potential fecal transmission of SARS-CoV-2: current evidence and implications for public health The novel coronavirus 2019 epidemic and kidneys Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade The outbreak of COVID-19: an overview Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes Coronavirus envelope protein: current knowledge The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles First line of defense: the role of the intestinal epithelium as an active component of the mucosal immune system Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion Neutrophils as components of mucosal homeostasis Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients SARS coronavirus and innate immunity Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells Monocyte recruitment during infection and inflammation Molecular immune pathogenesis and diagnosis of COVID-19 SARS and MERS: recent insights into emerging coronaviruses Mechanisms of innate immune evasion in re-emerging RNA viruses Innate immune evasion by human respiratory RNA viruses Interaction of SARS and MERS coronaviruses with the antiviral interferon response Cellular immune responses to severe acute respiratory syndrome coronavirus infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study Clinical Characteristics of Coronavirus Disease 2019 in China T cell responses to whole SARS coronavirus in humans TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib Clinical features of patients infected with 2019 novel coronavirus in Wuhan Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? Role of regulatory T cells in coronavirus-induced acute encephalitis Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it? Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection Persistent memory CD4+ and CD8+ T-cell responses in recovered severe acute respiratory syndrome (SARS) patients to SARS coronavirus M antigen Human CD4+ memory T-lymphocyte responses to SARS coronavirus infection Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors Neutralization of virus infectivity by antibodies: old problems in new perspectives Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus Interaction of antigens and antibodies at mucosal surfaces Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27 :e1002859. 51. den Boon JA, Ahlquist P. Organelle-like membrane compartmentalization of positive-strand RNA virus replication factories Biogenesis and architecture of arterivirus replication organelles Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis The innate immune system in the gastrointestinal tract: role of intraepithelial lymphocytes and lamina propria innate lymphoid cells in intestinal inflammation Intraepithelial lymphocytes: exploring the third way in immunology Small intestinal CD8+ TCRγδ+ NKG2A+ intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac disease A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity COVID-19 and Multiorgan Response Antigen sampling across epithelial barriers and induction of mucosal immune responses Evidence for gastrointestinal infection of SARS-CoV-2 COVID-19 and the digestive system Gastrointestinal implications in COVID-19 SARS-CoV-2 receptor ACE2 gene expression in small intestine correlates with age ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation ACE2 -from the renin-angiotensin system to gut microbiota and malnutrition Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome Gut-lung axis and dysbiosis in COVID-19 COVID-19 pandemic: pathophysiology and manifestations from the gastrointestinal tract SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19 SARS-CoV-2 and liver damage: a possible pathogenetic link Immunological co-ordination between gut and lungs in SARS-CoV-2 infection Gastrointestinal features in COVID-19 and the possibility of faecal transmission Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection Intestinal ion transport and the pathophysiology of diarrhea Immunobiotics for the bovine host: their interaction with intestinal epithelial cells and their effect on antiviral immunity Tight junction protein occludin is a porcine epidemic diarrhea virus entry factor Infectious diarrhea: cellular and molecular mechanisms Crossing barriers: infections of the lung and the gut Viral replication in the nasopharynx is associated with diarrhea in patients with severe acute respiratory syndrome Evaluation of the frequency of gastrointestinal symptoms and liver test disorder in patients during the Covid-19 outbreak in the Military Unit: a single-center pilot study Clinical characteristics and outcomes of COVID-19 patients with gastrointestinal symptoms admitted to Jianghan Fangcang Shelter Hospital in Wuhan Don't overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19) What is the role of supplementation with ascorbic acid, zinc, vitamin D, or N-acetylcysteine for prevention or treatment of COVID-19? Effects of COVID-19 on the Gut and the Liver-A Case Series of 711 Patients Outcomes and implications of diarrhea in patients with SARS-CoV-2 infection GI symptoms as early signs of COVID-19 in hospitalised Italian patients Clinical characteristics and predictors of mortality in African-Americans with COVID-19 from an inner-city community teaching hospital in New York Clinical characteristics of Covid-19 in New York City Prevalence and characteristics of gastrointestinal symptoms in patients with severe acute respiratory syndrome coronavirus 2 infection in the United States: a multicenter cohort study Effect of gastrointestinal symptoms in patients with COVID-19 Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan. China Association of digestive symptoms and hospitalization in patients with SARS-CoV-2 infection. medRxiv Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes Place and causes of acute cardiovascular mortality during the COVID-19 pandemic Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 -COVID-NET, 14 states Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19) Gastrointestinal symptoms and outcomes in hospitalized coronavirus disease 2019 patients Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city High prevalence of asthma in elderly women: findings from a Korean National Health Database and Adult Asthma Cohort Presumed asymptomatic carrier transmission of COVID-19 Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua xin xue guan bing za zhi Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19 Clinical features and short-term outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study Children with Covid-19 in pediatric emergency departments in Italy Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2 The clinical and chest CT features associated with severe and critical COVID-19 pneumonia Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study Clinical characteristics of imported cases of coronavirus disease 2019 (COVID-19) in Jiangsu province: a multicenter descriptive study Chest CT findings in patients with coronavirus disease 2019 and its relationship with clinical features Clinical and laboratory profiles of 75 hospitalized patients with novel coronavirus disease 2019 in Hefei. China. medRxiv Clinical features of 69 cases with coronavirus disease Epidemiological, clinical characteristics and outcome of medical staff infected with COVID-19 in Wuhan, China: a retrospective case series analysis. medRxiv Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series CT Features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China Loss of taste and smell are common clinical characteristics of patients with COVID-19 in Somalia: a retrospective double centre study Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong Cohort: systematic review and meta-analysis Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2 Digestive symptoms of COVID-19 and expression of ACE2 in digestive tract organs Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changes Faecal calprotectin indicates intestinal inflammation in COVID-19 Euro surveillance : bulletin Europeen sur les maladies transmissibles = Eur Commun Dis Bull Clinical and epidemiological characteristics of pediatric SARS-CoV-2 infections in China: a multicenter case series Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: a retrospective single center analysis Clinical analysis of 31 cases of 2019 novel coronavirus infection in children from six provinces (autonomous region) of northern China Comparison of the clinical characteristics between RNA positive and negative patients clinically diagnosed with coronavirus disease Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberculosis Respirat Dis Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberculosis Respirat Dis Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea. Osong Public Health and Research Perspectives Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19) Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore SARS-CoV-2 viral load in upper respiratory specimens of infected patients The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China Nosocomial infection with SARS-Cov-2 within departments of digestive surgery Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberculosis Respirat Dis Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Intestinal homeostasis and its breakdown in inflammatory bowel disease Inflammatory bowel disease registry and monitoring: feasibility study and application (Isfahan Inflammatory Bowel Disease Surveillance Project) Ulcerative colitis and Crohn's disease Management of inflammatory bowel disease patients in the COVID-19 pandemic era: a Brazilian tertiary referral center guidance Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target? Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection? Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: a pilot study COVID-19 and immunomodulation in IBD Inflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritis In vivo molecular imaging using fluorescent anti-TNF antibodies predicts response to biological therapy in Crohn's disease Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition Roles of the immune system in cancer: from tumor initiation to metastatic progression Inhibitory receptors and pathways of lymphocytes: the role of PD-1 in Treg development and their involvement in autoimmunity onset and cancer progression Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease The role of the immune system in kidney disease The immune system and kidney disease: basic concepts and clinical implications Immune cell dysfunction and inflammation in endstage renal disease How the innate immune system senses trouble and causes trouble Quantification of dendritic cell subsets in human renal tissue under normal and pathological conditions Characterization and distribution of interstitial cell types in the renal cortex of rats ACE2 alterations in kidney disease Single-cell analysis of ACE2 expression in human kidneys and bladders reveals a potential route of 2019-nCoV infection The gut-kidney axis in chronic renal failure: a new potential target for therapy Gut-organ axis: a microbial outreach and networking The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease The Gut-Kidney axis: putative interconnections between gastrointestinal and renal disorders Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease Caution on Kidney Dysfunctions of COVID-19 Patients Kidney Dysfunctions of COVID-19 Patients: A Multi-Centered, Retrospective, Observational Study Drug-induced nephrotoxicity Drug-induced nephrotoxicity Poisoning in the Modern World-New Tricks for an Old Dog Drug-induced renal disorders Acute renal impairment in coronavirus-associated severe acute respiratory syndrome IL-6 as a keystone cytokine in health and disease An interferon-γ-related cytokine storm in SARS patients Acute kidney injury in COVID-19; a review on current knowledge Coronavirus-nephropathy; renal involvement in COVID-19 SARS-associated coronavirus replication in cell lines Kidney impairment is associated with in-hospital death of COVID-19 patients A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence Updates on coronavirus (COVID-19) and kidney B lymphopenia in uremia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2. Nephrol Dialysis Transplant: Off Publ Eur Dialysis Transplant Assoc Maintenance hemodialysis and coronavirus disease 2019 (COVID-19): saving lives with caution, care, and courage SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19 Gastrointestinal manifestations in COVID-19 infection and its practical applications Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty Management of acute kidney injury in patients with COVID-19 Management of acute kidney injury in coronavirus disease 2019 The authors would like to thank Poursina Hakim Digestive Diseases Research Center for the support of this study and Anasik Lalazaryan for the designing of the figures.